Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer

NCT02551432 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT02551432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
February 28, 2018
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer